Organization
Aragon Pharmaceuticals, Inc.
Topic
All Topics
People
Find news about people
Alumni
Find news on alumni of any org
Industries
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed
Aragon Pharmaceuticals, Inc.
... include the conduct of existing respective operations through its totally-held subsidiary, Farallon, Inc. ("Farallon"), and through Prestige Liquids, LLC ("Prestige"), Monochrome Corp. ("Monochrome"), and Azure ...
... NEWSWIRE) -- Via OTC PR Wire ---Â Â After extensive due diligence Farallon, Inc. a wholly-owned subsidiary of IDGlobal Corp. (USOTC:IDGC) is pleased to announce ...
... CSO. “The Column Group worked with Dr. Sawyers and Dr. Heyman at Aragon Pharmaceuticals and Seragon Pharmaceuticals, and we have tremendous confidence in their ability, ...
... Guidewire Software, Seragon / Aragon Pharmaceuticals, and WeWork will receive EY's 2015 Venture Capital Award of Excellence, ...
... Two Jinn; and (Not pictured) Dr. Rich Heyman, CEO - Seragon / Aragon Pharmaceuticals. (Photo: Business Wire) EY Entrepreneur Of The Year is the world's ...
... to joining ProNAi, Dr. You served as the Chief Business Officer of Aragon Pharmaceuticals, a private oncology drug discovery and development company, where she was ...
... contributed to the formation of startups, especially in biotechnology. The spinoffs include Aragon Pharmaceuticals, sold in 2013 to Johnson & Johnson for up to $1 ...
... experimental breast cancer treatment prove viable. Seragon was spun out of Aragon Pharmaceuticals Inc. after Johnson & Johnson agreed to buy Aragon last fall for ...
... cancer, Zytiga, and is committed to paying up to $1 billion for Aragon Pharmaceuticals' experimental prostate cancer drugs. But Molina thinks these therapies could be ...
... Janssen, as exemplified by the recent Johnson & Johnson acquisition of Aragon Pharmaceuticals, Inc. and ARN-509, an investigational second-generation androgen receptor signaling inhibitor. Janssen is ...
Subscribe now for full coverage on Aragon Pharmaceuticals, Inc.
Start My Free Trial